bioRxivMicrobiology
GSMN-ML- a genome scale metabolic network reconstruction of the obligate human pathogen Mycobacterium leprae
K. Borah, J. Kearney, R. Banerjee, P. Vats, H. Wu, S. Dahale, S. Manjari, R. Joshi, B. Bonde, O. Ojo, R. Lahiri, D. Williams, J. McFadden
Abstract
Leprosy, caused by Mycobacterium leprae, has plagued humanity for thousands of years and continues to cause morbidity, disability and stigmatization in two to three million people today. Although effective treatment is available, the disease incidence has remained approximately constant for decades so new approaches, such as vaccine or new drugs, are urgently needed for control. Research is however hampered by the pathogens obligate intracellular lifestyle and the fact that it has never been grown in vitro. Consequently, despite the availability of its complete genome sequence, fundamental questions regarding the biology of the pathogen, such as its metabolism, remain largely unexplored. In order to explore the metabolism of the leprosy bacillus with a long-term aim of developing a medium to grow the pathogen in vitro, we reconstructed an in silico genome scale metabolic model of the bacillus, GSMN-ML. The model was used to explore the growth and biomass production capabilities of the pathogen with a range of nutrient sources, such as amino acids, glucose, glycerol and metabolic intermediates. We also used the model to analyze RNA-seq data from M. leprae grown in mouse foot pads, and performed Differential Producibility Analysis (DPA) to identify metabolic pathways that appear to be active during intracellular growth of the pathogen, which included pathways for central carbon metabolism, co-factor, lipids, amino acids, nucleotides and cell wall synthesis. The GSMN-ML model is thereby a useful in silico tool that can be used to explore the metabolism of the leprosy bacillus, analyze functional genomic experimental data, generate predictions of nutrients required for growth of the bacillus in vitro and identify novel drug targets.\n\nAuthor SummaryMycobacterium leprae, the obligate human pathogen is uncultivable in axenic growth medium, and this hinders research on this pathogen, and the pathogenesis of leprosy. The development of novel therapeutics relies on the understanding of growth, survival and metabolism of this bacterium in the host, the knowledge of which is currently very limited. Here we reconstructed a metabolic network of M. leprae-GSMN-ML, a powerful in silico tool to study growth and metabolism of the leprosy bacillus. We demonstrate the application of GSMN-ML to identify the metabolic pathways, and metabolite classes that M. leprae utilizes during intracellular growth.
- organism: human
- assay: metabolomics
- research focus: drug response / drug discovery
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mycobacterial Metabolic Model Development for Drug Target Identification
Bridget P. Bannerman, Alexandru Oarga, Jorge Júlvez·GigabytePeer-reviewed·Apr 30, 2023
- Soil bacterium Massilia secretes metabolites that promote Leptospira growth
Michinobu Yoshimura, Ryo Ozuru, … Kenji Hiromatsu·bioRxiv·Apr 7, 2026
- Nutrient control enables metabolic reconstruction of L. rhamnosus GG and analysis of secretions
Gracelyn R. Richmond, Emanuel Cunha, … Roger Chang·mSystemsPeer-reviewed·Oct 28, 2026
- Model-driven design allows growth of Mycoplasma pneumoniae on serum-free media
Erika Gaspari, Antoni N. Malachowski, … Maria Suarez Diez·npj Systems Biology and ApplicationsPeer-reviewed·Oct 23, 2020
- Integrative Computational Framework for Understanding Metabolic Modulation in Leishmania
Nutan Chauhan, Shailza Singh·Frontiers in Bioengineering and BiotechnologyPeer-reviewed·Nov 18, 2019
- METABOLIC MODELLING AS A POWERFUL TOOL TO IDENTIFY CRITICAL COMPONENTS OF THE PNEUMOCYSTIS GROWTH MEDIUM
Olga A. Nev, Elena Zamaraeva, … Alistair J. P. Brown·bioRxiv·Jun 7, 2023